BOJI CRO

Wallstreetcn · Jan 14 at 07:50 PM

AI healthcare and AI pharmaceutical concepts are experiencing volatile adjustments, with PR falling over 18%, R&G Pharma down nearly 15%, and IMIC, BOJI CRO, GOODWILL, and Berry Genomics all dropping more than 5%

Zhitong · Oct 28, 2025 at 08:09 AM

BOJI CRO released its performance for the first three quarters, with a net profit attributable to the parent company of 21.9139 million yuan, a decrease of 49.36%

Zhitong · Oct 23, 2025 at 05:05 AM

BOJI CRO: Subsidiary Guangzhou Huasheng Pharmaceutical has obtained a drug registration certificate

Zhitong · Sep 25, 2025 at 03:15 AM

Xiao Fang Pharma entrusts BOJI CRO to develop traditional Chinese medicine Class 1 new drug "Compound Arborvitae Tincture" (indication for hair loss)

Zhitong · Sep 19, 2025 at 02:59 AM

BOJI CRO obtained an invention patent for the "Method for Determining Gallic Acid in Berberine."

Zhitong · Sep 3, 2025 at 02:59 AM

BOJI CRO: "FCZR" has received the drug clinical trial approval notice